PVLA
Palvella Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 1 | $138 | +1 | n/a |
| Q2 2026 | 82 | +9 | 6.93M | $1.05B | +11 | −2 |
| Q1 2026 | 76 | +14 | 6.06M | $750.08M | +17 | −3 |
| Q4 2025 | 62 | +2 | 4.35M | $454.99M | +2 | n/a |
| Q3 2025 | 14 | +3 | 2.25M | $140.88M | +4 | −1 |
| Q2 2025 | 8 | 0 | 1.30M | $29.21M | n/a | n/a |
| Q1 2025 | 5 | +2 | 421.70K | $11.80M | +3 | −1 |
| Q4 2024 | 3 | +3 | 46.05K | $552,635 | +3 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assetmark, Inc | 1 | New | $138 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Assetmark, Inc | $138 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 13.20M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $252,559
Officer · 1.66K sh · $208,149
Officer · 607 sh · $76,600
Director · 2.07K sh · $254,058
Director · 476 sh · $57,663
Director · 505 sh · $63,910
Director · 597 sh · $74,820
Director · 920 sh · $114,416
Director · 2.60K sh · $321,046
Director · 2.00K sh · $257,555
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology